SEVENTH BASE PROSPECTUS SUPPLEMENT

Morgan Stanley

(incorporated under the laws of the State of Delaware in the United States of America)

BASE PROSPECTUS FOR THE ISSUANCE OF NOTES, SERIES A AND SERIES B UNDER THE REGULATION S PROGRAM FOR THE ISSUANCE OF NOTES, SERIES A AND B, WARRANTS AND CERTIFICATES

Morgan Stanley ("Morgan Stanley" or the "Issuer"), has prepared this seventh base prospectus supplement (the "Seventh Base Prospectus Supplement") to supplement and be read in conjunction with the base prospectus dated 19 July 2022 of Morgan Stanley (as supplemented by the first supplement to the Base Prospectus dated 24 August 2022, the second supplement to the Base Prospectus dated 3 November 2022, the third supplement to the Base Prospectus dated 17 November 2022, the fourth supplement to the Base Prospectus dated 23 January 2023, the fifth supplement to the Base Prospectus dated 16 March 2023, and the sixth supplement to the Base Prospectus dated 27 April 2023, the "Base Prospectus") relating to the Regulation S Program for the Issuance of Notes, Series A and Series B, Warrants and Certificates.

This Seventh Base Prospectus Supplement has been approved by the Luxembourg *Commission de Surveillance du Secteur Financier* (the "CSSF"), as competent authority under Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and constitutes a supplement for the purposes of Article 23(1) of the Prospectus Regulation.

The CSSF only approves this Seventh Base Prospectus Supplement as meeting the standard of completeness, comprehensibility and consistency imposed by the Prospectus Regulation and the CSSF gives no undertaking as to the economic and financial soundness of any transaction or the quality or solvency of the Issuer. Such approval should not be considered as an endorsement of the Issuers or the quality of the Notes that are the subject of this Seventh Base Prospectus Supplement.

This Seventh Base Prospectus Supplement has also been approved by the Luxembourg Stock Exchange pursuant to the rules and regulations of the Luxembourg Stock Exchange with respect to Exempt Notes for the purpose of providing information with regard to Program Securities for the purpose of listing Program Securities on the Official List and to trading on the Euro MTF market of the Luxembourg Stock Exchange. The Euro MTF market is not a regulated market for the purposes of MiFID II. The CSSF has neither approved nor reviewed information contained in this Seventh Base Prospectus Supplement in connection with the issue of any Exempt Notes.

Unless otherwise defined in this Seventh Base Prospectus Supplement, terms defined in the Base Prospectus shall have the same meaning when used in this Seventh Base Prospectus Supplement. To the extent that there is any inconsistency between any statement in this Seventh Base Prospectus Supplement and any other statement in, or incorporated by reference in, the Base Prospectus, the statements in this Seventh Base Prospectus Supplement will prevail.

The purpose of this Seventh Base Prospectus Supplement is to:

- (a) disclose the publication by Morgan Stanley of its Quarterly Report on Form 10-Q for the quarterly period ended 31 March 2023 (the "Morgan Stanley March 2023 Form 10-Q");
- (b) incorporate the Morgan Stanley March 2023 Form 10-Q by reference into the Base Prospectus, as set out in "Part A" of this Seventh Base Prospectus Supplement;
- (c) incorporate the fourth supplement to the Registration Document of Morgan Stanley, Morgan Stanley & Co. International plc, Morgan Stanley B.V. and Morgan Stanley Finance LLC dated 11 May 2023 (the "Fourth Supplement to the Registration Document") by reference into the Base Prospectus, as set out in "Part A" of this Seventh Base Prospectus Supplement;
- (d) make certain consequential amendments to the "General Information" section in the Base Prospectus, as set out in "Part B" of this Seventh Base Prospectus Supplement; and

(e) make certain amendments to the "Selected Financial Information of Morgan Stanley" section in the Base Prospectus pursuant to the publication of the Morgan Stanley March 2023 Form 10-Q, as set out in "Part C" of this Seventh Base Prospectus Supplement.

In accordance with Article 23.2 of the Prospectus Regulation, investors who have agreed to purchase or subscribe for, or have applied to purchase or subscribe for, any Notes prior to the publication of this Seventh Base Prospectus Supplement and where Securities had not yet been delivered to the investors at the time when the significant new factor, material mistake or material inaccuracy arose or was noted, shall have the right, exercisable within two Business Days following the date of publication of this Seventh Base Prospectus Supplement, to withdraw their acceptances or applications by notice in writing to the relevant Issuer or Manager, as the case may be. The final date within which such right of withdrawal must be exercised is 16 May 2023.

Save as disclosed in this Seventh Base Prospectus Supplement, no significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus has arisen since the publication of the Base Prospectus.

Morgan Stanley accepts responsibility for the information contained in this Seventh Base Prospectus Supplement. To the best of the knowledge and belief of Morgan Stanley, the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

This Seventh Base Prospectus Supplement is available for viewing, and copies may be obtained from, the officers of the Issuers and the Paying Agents.

This Seventh Base Prospectus Supplement is available on Morgan Stanley's website at http://sp.morganstanley.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and on the website of the Luxembourg Stock Exchange at www.luxse.com/EU/Documents and stock the stock of the st

The Morgan Stanley March 2023 Form 10-Q is available on Morgan Stanley's website at https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=23c80e84-f1c9-4938-8fcd-78d0df08ad8e and on the website of the Luxembourg Stock Exchange at www.luxse.com.

The Fourth Supplement to the Registration Document is available on Morgan Stanley's website at https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=db998d9d-fff1-4d6d-8be6-0f187e1b8855 and on the website of the Luxembourg Stock Exchange at www.luxse.com.

12 May 2023

MORGAN STANLEY

CONTENTS

	Page(s)
PART A – INCORPORATION BY REFERENCE	4-5
PART B – AMENDMENTS TO THE "GENERAL INFORMATION" SECTION	6
PART C – AMENDMENTS TO THE "SELECTED FINANCIAL INFORMATION OF MORGAN STANLEY" SECTION	7

PART A – INCORPORATION BY REFERENCE

This Seventh Base Prospectus Supplement incorporates by reference the Morgan Stanley March 2023 Form 10-Q and supplements the section entitled "*Incorporation by Reference*" contained on pages 29-38 of the Base Prospectus.

The information incorporated by reference must be read in conjunction with the cross-reference table below which supplements the table of information incorporated by reference in the section entitled "*Incorporation by Reference*" contained on pages 29-38 of the Base Prospectus.

The following document and/or information shall be deemed to be incorporated by reference in, and to form part of, the Base Prospectus:

Document filed		Information incorporated by reference	Page(s)
Form 10-Q for the quarterly period ended 31 March 2023			
https://sp.morganstanley.com/EU/Download/GeneralDocument?document ID=23c80e84-f1c9-4938-8fcd-	(2)	Quantitative and Qualitative Disclosures a Risk	about 23-31
78d0df08ad8e	(3)	Report of Independent Registered P Accounting Firm	ublic 32
	(4)	Consolidated Financial Statements and Notes	33-65
	(5)	Consolidated Income Statement (Unaudited)	33
		(i) Consolidated Comprehensive Inc Statement (Unaudited)	come 33
		(ii) Consolidated Balance Sheet (Unaudit March 31, 2023)	ed at 34
		(iii) Consolidated Statement of Change Total Equity (Unaudited)	es in 35
		(iv) Consolidated Cash Flow State (Unaudited)	ment 36
		(v) Notes to Consolidated Financial Staten (Unaudited)	nents 37-65
	(6)	Financial Data Supplement (Unaudited)	66
	(7)	Glossary of Common Terms and Acronyms	67
	(8)	Controls and Procedures	68
	(9)	Legal Proceedings	68
	(10)	Unregistered Sales of Equity Securities and U Proceeds	se of 68
	(11)	Other Information	69
	(12)	Signatures	69

Fourth Supplement to the Registration Document	(1)	Part B – Amendments to "Information Incorporated by Reference" section	7
https://sp.morganstanley.com/EU/Download/GeneralDocument?document ID=db998d9d-fff1-4d6d-8be6- 0f187e1b8855	(2)	Part C – Amendments to "Description of Morgan Stanley" section	8

Any non-incorporated parts of a document referred to herein are either deemed not relevant for an investor or are otherwise covered elsewhere in the Base Prospectus.

PART B – AMENDMENTS TO THE "GENERAL INFORMATION" SECTION

1. Sub-paragraph (d) under the heading "*Documents available*" on page 204 of the Base Prospectus shall be deleted in its entirety and the following substituted therefor:

"Morgan Stanley's Annual Report on Form 10-K for the year ended 31 December 2022, Morgan Stanley's Current Reports on Form 8-K dated 17 January 2023 and 19 April 2023, Morgan Stanley's Quarterly Reports on Form 10-Q for the quarterly period ended 31 March 2023 and Morgan Stanley's Proxy Statement dated 6 April 2023;"

2. The section titled "No material adverse change in prospects and no significant change in the financial performance and financial position" on page 205 of the Base Prospectus shall be deleted in its entirety and the following substituted therefor:

"No material adverse change in prospects and no significant change in the financial performance and financial position

There has been no material adverse change in the prospects of Morgan Stanley since 31 December 2022, the date of the last published annual audited financial statements of Morgan Stanley.

There has been no significant change in the financial performance and financial position of Morgan Stanley since 31 March 2023, the date of the latest published interim (unaudited) financial statements of Morgan Stanley."

3. Sub-paragraph (b) of the sub-section titled "Legal and arbitration proceedings" on page 205 of the Base Prospectus shall be deleted in its entirety and the following substituted therefor:

"(b) the paragraphs beginning with "Legal" under the heading "Contingencies" under the heading "Commitments, Guarantees and Contingencies" in "Notes to Consolidated Financial Statements (Unaudited) at pages 56-57 and the section entitled "Legal Proceedings" at page 68 of Morgan Stanley's Quarterly Report on Form 10-Q for the quarterly period ended 31 March 2023; and"

PART C - AMENDMENTS TO THE "SELECTED FINANCIAL INFORMATION OF MORGAN STANLEY" SECTION

1. The section entitled "Selected Financial Information of Morgan Stanley" on page 26 of the Base Prospectus shall be deleted in its entirety and the following substituted therefor:

SELECTED FINANCIAL INFORMATION OF MORGAN STANLEY

This section contains selected financial information of Morgan Stanley relating to the year ended 31 December 2022 and the three months ended 31 March 2023.

The information in respect of the year ended 31 December 2022 set out below is derived from the audited financial statements included in Morgan Stanley's Annual Report on Form 10-K for the year ended 31 December 2022.

The information in respect of the three months ended 31 March 2023 set out below is derived from the unaudited financial statements included in Morgan Stanley's Quarterly Report on Form 10-Q for the quarterly period ended 31 March 2023.

Consolidated Balance Sheet (U.S.\$ in millions)	At 31 March 2023 (unaudited)	At 31 December 2022	At 31 December 2021
Total assets	1,199,904	1,180,231	1,188,140
Total liabilities and equity	1,199,904	1,180,231	1,188,140

Consolidated Income Statement (in U.S.\$ millions)	Three months ended 31 March 2023 (unaudited)	Three months ended 31 March 2022 (unaudited)	2022	2021
Net revenues	14,517	14,801	53,668	59,755
Income before provision for income taxes	3,760	4,588	14,089	19,668
Net Income	3,033	3,715	11,179	15,120